Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (ATRA) is a clinical-stage biopharmaceutical company developing allogeneic T-cell immunotherapies for cancer and serious diseases. The company's news flow typically centers on clinical trial updates, regulatory developments, financial results, and progress in its collaboration with Memorial Sloan Kettering Cancer Center.
For investors tracking ATRA, news coverage focuses on several key areas. Regulatory announcements related to investigational new drug applications, clinical trial authorizations, and interactions with health authorities provide insight into product development timelines. Clinical data releases from ongoing trials of the company's T-cell therapy candidates offer evidence of safety and efficacy that drives valuation. Financial updates including quarterly results and capital raises reveal the company's cash runway and ability to fund multi-year clinical programs.
As a development-stage biotech company, Atara's newsworthy events also include partnership developments related to its MSK collaboration, pipeline updates on product candidates targeting EBV, CMV, and WT1-associated diseases, and manufacturing milestones for its allogeneic cell therapy platform. The company periodically announces leadership changes, intellectual property developments, and presentations at medical conferences that detail scientific progress.
This news page aggregates ATRA announcements and coverage to help you monitor developments that may affect the company's path toward potential product approvals and commercialization. Bookmark this page to track regulatory progress, clinical trial outcomes, and strategic decisions that shape Atara Biotherapeutics' position in the immunotherapy sector.
Atara Biotherapeutics announced promising results for ATA2271, a CAR T-cell therapy targeting mesothelioma, at the ESMO I-O Congress. Early data show that ATA2271 demonstrates good safety and significant persistence in patients after four weeks, with no severe adverse events reported. The therapy aims to improve outcomes in advanced mesothelioma, where median survival is only 9-17 months despite standard treatments. In vivo studies indicate that ATA2271 can eradicate tumors in mice, highlighting its potential in treating challenging solid tumors.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) announced the grant of 21,438 restricted stock units and stock options to newly hired employees, as part of the 2018 Inducement Plan, with the grants dated December 1, 2021. The restricted stock units vest over four years, while the stock options, priced at $17.36 each, also follow a four-year vesting period. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent critical for the company's mission in T-cell immunotherapy.
Atara Biotherapeutics has announced that the European Medicines Agency (EMA) has fully validated the Marketing Authorization Application (MAA) for its investigational treatment tabelecleucel (tab-cel). This therapy targets Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare and aggressive cancer with no approved options. The MAA will be evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP), with a decision expected in the second half of 2022. Tab-cel has shown a 50% objective response rate in clinical trials, demonstrating significant potential for this patient population.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced that CEO Pascal Touchon will participate in three virtual conferences. These include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 9:45 a.m. EST, the Stifel 2021 Virtual Healthcare Conference, also on November 15, 2021, at 4:40 p.m. EST, and the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 10:05 a.m. EST. Live webcasts will be available on their website, with archived replays accessible for 30 days.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has granted 52,474 restricted stock units and 5,618 stock options to newly hired employees as part of its employee inducement plan. The stock units will vest over four years, while the stock options have a ten-year term with an exercise price of $16.51, aligned with the closing price on the grant date of November 1, 2021. This initiative aims to attract talent under Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics announced significant results from its Phase 3 ALLELE study of tabelecleucel (tab-cel), showing a 50% objective response rate (ORR) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The one-year survival rate for responders reached 89.2%, indicating a substantial survival advantage. Safety data remained consistent, with no new concerns. The findings will be presented at the American Society of Hematology Annual Meeting in December 2021, highlighting tab-cel’s transformative potential in treating EBV-driven diseases.
Atara Biotherapeutics (Nasdaq: ATRA) reported Q3 2021 results, highlighting significant progress in its pipeline, including pivotal Phase 3 data for tab-cel®, accepted for oral presentation at the American Society of Hematology meeting. The company plans to submit its EU Marketing Authorization Application imminently, with an FDA Biologics License Application expected in Q2 2022. Notable advancements also include promising data for ATA188 in treating progressive MS and ongoing development of CAR T therapies. Financially, Atara reported an $84.7 million net loss for Q3, reflecting increased R&D and operational expenses.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its third quarter 2021 financial results on Thursday, November 4, 2021, before the market opens. Following this, a live conference call will take place at 8:30 a.m. EDT for analysts and investors to discuss the results and provide corporate updates. Atara is recognized for its innovative T-cell immunotherapy platform focused on treating cancers and autoimmune diseases, with lead programs in advanced clinical development, particularly targeting Epstein-Barr virus-related ailments.
Atara Biotherapeutics (ATRA) announced promising data from its Phase 1 clinical study of ATA188, a T-cell immunotherapy targeting EBV-infected cells in progressive multiple sclerosis (MS) patients. The interim analysis highlights significant sustained disability improvement in 7 of 8 patients, alongside increased magnetization transfer ratio (MTR) readings suggestive of remyelination. The ongoing open-label extension study tracked these patients for up to 39 months, with no new adverse effects noted. Atara plans to conduct an interim analysis from its randomized Phase 2 EMBOLD study in H1 2022.
Atara Biotherapeutics and Pierre Fabre have signed an exclusive commercialization agreement for Tab-cel® in Europe, the Middle East, Africa, and select emerging markets, targeting EBV-positive cancers. Atara will receive an upfront payment of USD 45 million, with potential milestone payments of up to USD 320 million, plus tiered royalties from net sales. Atara retains commercialization rights in the US and other major markets. The EU Marketing Authorization Application for Tab-cel® is on track for submission in November 2021.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
